| Pulmonary arterial hypertension
Adempass vs Letairis
Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.Deep comparison between: Adempas vs Letairis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLetairis has a higher rate of injection site reactions vs Adempas based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Letairis but not Adempas, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Adempas
Letairis
At A Glance
Oral
Three times daily
Soluble guanylate cyclase (sGC) stimulator
Oral
Daily
Endothelin receptor antagonist
Indications
- Chronic thromboembolic pulmonary hypertension
- Pulmonary arterial hypertension
- Pulmonary arterial hypertension
Dosing
Chronic thromboembolic pulmonary hypertension, Pulmonary arterial hypertension Start at 1 mg three times a day (or 0.5 mg if hypotension risk); increase by 0.5 mg no sooner than every 2 weeks as tolerated, to a maximum of 2.5 mg three times a day.
Pulmonary arterial hypertension Initiate at 5 mg once daily, with or without tadalafil 20 mg once daily; titrate at 4-week intervals as needed and tolerated to Letairis 10 mg or tadalafil 40 mg; do not split, crush, or chew tablets.
Contraindications
- Pregnancy
- Concomitant use of nitrates or nitric oxide donors in any form
- Concomitant use of PDE-5 inhibitors (sildenafil, tadalafil, or vardenafil) or nonspecific PDE inhibitors (dipyridamole or theophylline)
- Concomitant use of other soluble guanylate cyclase (sGC) stimulators
- Pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP)
- Pregnancy (Letairis may cause fetal harm when administered to a pregnant female)
- Idiopathic Pulmonary Fibrosis, including IPF patients with pulmonary hypertension (WHO Group 3)
Adverse Reactions
Most common (>=3%) Headache, dyspepsia and gastritis, dizziness, nausea, diarrhea, hypotension, vomiting, anemia, gastroesophageal reflux disease, constipation
Serious Embryo-fetal toxicity, hypotension, bleeding
Most common (>3% placebo-adjusted) Peripheral edema, nasal congestion, sinusitis, flushing
Postmarketing Anemia requiring transfusion, heart failure (associated with fluid retention), symptomatic hypotension, hypersensitivity (angioedema, rash), liver aminotransferase elevations (ALT, AST)
Pharmacology
Riociguat is a soluble guanylate cyclase (sGC) stimulator with a dual mode of action: it sensitizes sGC to endogenous nitric oxide (NO) by stabilizing the NO-sGC binding, and directly stimulates sGC via a separate binding site independently of NO, increasing cGMP generation and leading to vasodilation.
Ambrisentan is a high-affinity, selective ETA receptor antagonist that blocks the vasoconstriction and cell proliferation mediated by endothelin-1 (ET-1) in pulmonary vasculature, where ET-1 concentrations and mRNA are markedly elevated in PAH patients.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Adempas
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Letairis
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Adempas
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (6/8)
Letairis
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Adempas
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Letairis
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAdempas Co-pay Assistance Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/momo
Letairis Co-Pay Coupon ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdempasView full Adempas profile
LetairisView full Letairis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.